Cargando…
Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy
Several retrospective and a few prospective studies have shown that metastasis-directed therapy (MDT) could delay clinical progression and postpone the initiation of systemic treatment in oligorecurrent prostate cancer (PCa) patients. However, these endpoints are strongly influenced by variables suc...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464259/ https://www.ncbi.nlm.nih.gov/pubmed/32823690 http://dx.doi.org/10.3390/cancers12082271 |
_version_ | 1783577323428118528 |
---|---|
author | Devos, Gaëtan Berghen, Charlien Van Eecke, Henri Stichele, Arthur Vander Van Poppel, Hendrik Goffin, Karolien Mai, Cindy De Wever, Liesbeth Albersen, Maarten Everaerts, Wouter De Meerleer, Gert Joniau, Steven |
author_facet | Devos, Gaëtan Berghen, Charlien Van Eecke, Henri Stichele, Arthur Vander Van Poppel, Hendrik Goffin, Karolien Mai, Cindy De Wever, Liesbeth Albersen, Maarten Everaerts, Wouter De Meerleer, Gert Joniau, Steven |
author_sort | Devos, Gaëtan |
collection | PubMed |
description | Several retrospective and a few prospective studies have shown that metastasis-directed therapy (MDT) could delay clinical progression and postpone the initiation of systemic treatment in oligorecurrent prostate cancer (PCa) patients. However, these endpoints are strongly influenced by variables such as concomitant use of androgen deprivation therapy (ADT) and follow-up imaging protocols. The aim of this manuscript was to assess palliative ADT- and metastatic castration-resistant prostate cancer (mCRPC)-free survival as long-term oncological outcomes in oligorecurrent PCa treated by MDT. We retrospectively identified consecutive post-prostatectomy oligorecurrent PCa patients treated by MDT (salvage lymphadenectomy, radiotherapy, or metastasectomy) at our tertiary referral center. Patients were eligible for inclusion if they developed recurrence following radical prostatectomy, had ≤5 metastatic lesions on imaging and had a serum testosterone >50 ng/dL or a testosterone suppression therapy-free interval of >2 years prior to the first MDT as an assumption of recovered serum testosterone (if no testosterone measurement available). Patients with castration-resistant or synchronous oligometastatic PCa at the time of first MDT were excluded. Repeated MDTs were allowed, as well as a period of concomitant ADT. Kaplan–Meier analyses were performed to assess palliative ADT-free and mCRPC-free survival. We identified 191 eligible patients who underwent MDT. Median follow-up from first MDT until last follow-up or death was 45 months (IQR 27–70; mean 51 months). Estimated median palliative-ADT free survival was 66 months (95% CI 58–164) and estimated median mCRPC-free survival was not reached (mean 117 months, 95% CI 103–132). In total, 314 MDTs were performed and 25 patients (13%) received ≥3 MDTs. This study demonstrated that (repeated) MDT is feasible and holds promise in terms of palliative ADT-free and mCRPC-free survival for patients with oligorecurrent PCa. However, these findings should be confirmed in prospective randomized controlled trials. |
format | Online Article Text |
id | pubmed-7464259 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74642592020-09-04 Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy Devos, Gaëtan Berghen, Charlien Van Eecke, Henri Stichele, Arthur Vander Van Poppel, Hendrik Goffin, Karolien Mai, Cindy De Wever, Liesbeth Albersen, Maarten Everaerts, Wouter De Meerleer, Gert Joniau, Steven Cancers (Basel) Article Several retrospective and a few prospective studies have shown that metastasis-directed therapy (MDT) could delay clinical progression and postpone the initiation of systemic treatment in oligorecurrent prostate cancer (PCa) patients. However, these endpoints are strongly influenced by variables such as concomitant use of androgen deprivation therapy (ADT) and follow-up imaging protocols. The aim of this manuscript was to assess palliative ADT- and metastatic castration-resistant prostate cancer (mCRPC)-free survival as long-term oncological outcomes in oligorecurrent PCa treated by MDT. We retrospectively identified consecutive post-prostatectomy oligorecurrent PCa patients treated by MDT (salvage lymphadenectomy, radiotherapy, or metastasectomy) at our tertiary referral center. Patients were eligible for inclusion if they developed recurrence following radical prostatectomy, had ≤5 metastatic lesions on imaging and had a serum testosterone >50 ng/dL or a testosterone suppression therapy-free interval of >2 years prior to the first MDT as an assumption of recovered serum testosterone (if no testosterone measurement available). Patients with castration-resistant or synchronous oligometastatic PCa at the time of first MDT were excluded. Repeated MDTs were allowed, as well as a period of concomitant ADT. Kaplan–Meier analyses were performed to assess palliative ADT-free and mCRPC-free survival. We identified 191 eligible patients who underwent MDT. Median follow-up from first MDT until last follow-up or death was 45 months (IQR 27–70; mean 51 months). Estimated median palliative-ADT free survival was 66 months (95% CI 58–164) and estimated median mCRPC-free survival was not reached (mean 117 months, 95% CI 103–132). In total, 314 MDTs were performed and 25 patients (13%) received ≥3 MDTs. This study demonstrated that (repeated) MDT is feasible and holds promise in terms of palliative ADT-free and mCRPC-free survival for patients with oligorecurrent PCa. However, these findings should be confirmed in prospective randomized controlled trials. MDPI 2020-08-13 /pmc/articles/PMC7464259/ /pubmed/32823690 http://dx.doi.org/10.3390/cancers12082271 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Devos, Gaëtan Berghen, Charlien Van Eecke, Henri Stichele, Arthur Vander Van Poppel, Hendrik Goffin, Karolien Mai, Cindy De Wever, Liesbeth Albersen, Maarten Everaerts, Wouter De Meerleer, Gert Joniau, Steven Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy |
title | Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy |
title_full | Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy |
title_fullStr | Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy |
title_full_unstemmed | Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy |
title_short | Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy |
title_sort | oncological outcomes of metastasis-directed therapy in oligorecurrent prostate cancer patients following radical prostatectomy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464259/ https://www.ncbi.nlm.nih.gov/pubmed/32823690 http://dx.doi.org/10.3390/cancers12082271 |
work_keys_str_mv | AT devosgaetan oncologicaloutcomesofmetastasisdirectedtherapyinoligorecurrentprostatecancerpatientsfollowingradicalprostatectomy AT berghencharlien oncologicaloutcomesofmetastasisdirectedtherapyinoligorecurrentprostatecancerpatientsfollowingradicalprostatectomy AT vaneeckehenri oncologicaloutcomesofmetastasisdirectedtherapyinoligorecurrentprostatecancerpatientsfollowingradicalprostatectomy AT stichelearthurvander oncologicaloutcomesofmetastasisdirectedtherapyinoligorecurrentprostatecancerpatientsfollowingradicalprostatectomy AT vanpoppelhendrik oncologicaloutcomesofmetastasisdirectedtherapyinoligorecurrentprostatecancerpatientsfollowingradicalprostatectomy AT goffinkarolien oncologicaloutcomesofmetastasisdirectedtherapyinoligorecurrentprostatecancerpatientsfollowingradicalprostatectomy AT maicindy oncologicaloutcomesofmetastasisdirectedtherapyinoligorecurrentprostatecancerpatientsfollowingradicalprostatectomy AT deweverliesbeth oncologicaloutcomesofmetastasisdirectedtherapyinoligorecurrentprostatecancerpatientsfollowingradicalprostatectomy AT albersenmaarten oncologicaloutcomesofmetastasisdirectedtherapyinoligorecurrentprostatecancerpatientsfollowingradicalprostatectomy AT everaertswouter oncologicaloutcomesofmetastasisdirectedtherapyinoligorecurrentprostatecancerpatientsfollowingradicalprostatectomy AT demeerleergert oncologicaloutcomesofmetastasisdirectedtherapyinoligorecurrentprostatecancerpatientsfollowingradicalprostatectomy AT joniausteven oncologicaloutcomesofmetastasisdirectedtherapyinoligorecurrentprostatecancerpatientsfollowingradicalprostatectomy |